Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up

Mosna, Federico ; Papayannidis, Cristina ; Martinelli, Giovanni ; Bonalumi, Angela ; Tecchio, Cristina ; Candoni, Anna ; Capelli, Debora ; Piccin, Andrea ; Forghieri, Fabio ; Bigazzi, Catia ; Visani, Giuseppe ; Zambello, Renato ; Zanatta, Lucia ; Volpato, Francesca ; Paolini, Stefania ; Testoni, Nicoletta ; Gherlinzoni, Filippo ; Gottardi, Michele (2015) Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up. American Journal Of Hematology, 90 (6). pp. 471-575.
Full text disponibile come:
[img]
Anteprima
Documento PDF (Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up - pre-referee)
Licenza Creative Commons Attribution Non-commercial No Derivatives (CC BY-NC-ND 3.0)

Download (1MB) | Anteprima
[img]
Anteprima
Documento PDF (Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up - with referee)
Licenza Creative Commons Attribution Non-commercial No Derivatives (CC BY-NC-ND 3.0)

Download (1MB) | Anteprima

Abstract

Approximately 40% of patients affected by core binding factor (CBF) acute myeloid leukemia (AML) ultimately die from the disease. Few prognostic markers have been identified. In this study we reviewed 192 patients with core binding factor acute myeloid leukemia (AML), treated with curative intent (age, 15-79 years) in 11 Italian institutions. Overall, 10-year overall survival (OS), disease-free survival (DFS), and event-free survival were 63.9%, 54.8%, and 49.9%, respectively; patients with the t(8;21) and inv(16) chromosomal rearrangements exhibited significant differences at diagnosis. Despite similarly high complete remission (CR) rate, patients with inv(16) experienced superior DFS and a high chance of achieving a second CR, often leading to prolonged OS also after relapse. We found that a complex karyotype (ie, ≥4 cytogenetic anomalies) affected survival; the KIT D816 mutation predicted worse prognosis only in patients with the t(8;21) rearrangement, whereas FLT3 mutations had no prognostic impact. We then observed increasingly better survival with more intense first-line therapy, in some high-risk patients including autologous or allogeneic hematopoietic stem cell transplantation. In multivariate analysis, age, severe thrombocytopenia, elevated lactate dehydrogenase levels, and failure to achieve CR after induction independently predicted longer OS, whereas complex karyotype predicted shorter OS only in univariate analysis. The achievement of minimal residual disease negativity predicted better OS and DFS. Long-term survival was also observed in a minority of elderly patients who received intensive consolidation treatment. All considered, we identified also among CBF AML patients a subgroup with poorer prognosis who might benefit from more intense first-line treatment.

Abstract
Tipologia del documento
Articolo
Autori
AutoreAffiliazioneORCID
Mosna, Federico
Papayannidis, Cristina
Martinelli, Giovanni
Bonalumi, Angela
Tecchio, Cristina
Candoni, Anna
Capelli, Debora
Piccin, Andrea
Forghieri, Fabio
Bigazzi, Catia
Visani, Giuseppe
Zambello, Renato
Zanatta, Lucia
Volpato, Francesca
Paolini, Stefania
Testoni, Nicoletta
Gherlinzoni, Filippo
Gottardi, Michele
Parole chiave
Core Binding Factor; AML; chemotherapy; t(8;21); inv(16)
Settori scientifico-disciplinari
DOI
Data di deposito
07 Gen 2016 09:22
Ultima modifica
01 Giu 2016 21:00
Nome del Progetto
NGS-PTL - Next Generation Sequencing platform for targeted Personalized Therapy of Leukemia
Programma di finanziamento
EC - FP7
URI

Altri metadati

Statistica sui download

Statistica sui download

Gestione del documento: Visualizza il documento

^